ArticleJournal of the neurological sciences2023
New-onset headache following COVID-19: An Italian multicentre case series.
Article in Journal of the neurological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.
- Migraine-like headaches: a systematic review of secondary etiologies, clinical features and therapeutic patterns (1977-2024).The journal of headache and pain · 2025Pooled it
- Post-COVID-19 headache- NDPH phenotype: a systematic review of case reports.Frontiers in pain research (Lausanne, Switzerland) · 2024Pooled it
- The Impact of COVID-19 on Migraine: The Patients' Perspective.Life (Basel, Switzerland) · 2024Article
- Acute and Preventive Treatment of COVID-19-Related Headache: A Series of 100 Patients.Life (Basel, Switzerland) · 2024Article
- New insights into the increased risk of migraines from COVID-19 infection and vaccination: a Mendelian randomization study.Frontiers in neurology · 2024Article
- New daily persistent headache after SARS-CoV-2 infection in Latin America: a cross-sectional study.BMC infectious diseases · 2023Article
- Persistent Cognitive Dysfunction in a Non-Hospitalized COVID-19 Long-Hauler Patient Responding to Cognitive Rehabilitation and Citicoline Treatment.Brain sciences · 2023Article
- Altered metabolites in the periaqueductal gray of COVID-19 patients experiencing headaches: a longitudinal MRS study.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo describe the characteristics of patients with new-onset headache following SARS-CoV-2 infection.
backgroundSARS-CoV-2 infection leads to several neurological manifestations, and headache is a frequent and disabling symptom, both exacerbating pre-existing headache syndromes and causing new-onset ones.
methodsPatients with new-onset headache after SARS-CoV-2 infection with consent to participate were included, while those ones with previous headaches were excluded. The temporal latency of headache after infection, pain characteristics, and concomitant symptoms were analysed. Moreover, the efficacy of acute and preventive medications was explored.
resultsEleven females (median age 37.0 [10.0-60.0] years old) were included. In most cases, headache onset occurred with the infection, the location of pain varied, and the quality was either pulsating or tightening. Headache was persistent and daily in 8 patients (72.7%), while it occurred in episodes in the remaining subjects. Baseline diagnoses were new daily persistent headache (36.4%), probable new daily persistent headache (36.4%), probable migraine (9.1%), and migraine-like headache secondary to COVID-19 (18.2%). Ten patients received one or more preventive treatments and six of them showed an improvement.
conclusionNew-onset headache following COVID-19 is a heterogenous condition with uncertain pathogenesis. This type of headache can become persistent and severe, with a wide spectrum of manifestations (new daily persistent headache being the most represented one) and variable response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.